JPRN-UMIN000019450已完成未知
A Randomized, Double-blind, Placebo-Controlled, Parallel Group Comparison Study on the Effects of Daily Ingestion of Isoflavone -Rich Soybean, "Yukipirika" on the Improvement of Bone Metabolism and Menopausal Symptoms - The Effect of Daily Ingestion of the Soybean on the Improvement of Bone Metabolism and Menopausal Symptoms
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45years-old 至 65years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Subjects who are under treatment and medication for menopausal symptoms, osteoporosis and thyroid disease. 2. Subjects who are under treatment and medication for psychiatric disorders. 3. Subjects who are considered to have secondary osteoporosis (due to endocrine disorders, continuous use of steroids, etc.). 4. Subjects whose urinary productivity of equol is low. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, or gastrointestinal diseases, or affected with infectious diseases which are required to report to the authorities. 6. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with unusually high and/or low blood pressure or abnormal hematological data. 8. Subjects with serious anemia. 9. Subjects who are at risk of having allergic reactions to drugs or foods (especially soybean and wheat). 10. Subjects who regularly take medicine, functional foods and/or supplements (isoflavone, daidzein, genistein, glycitein, equol, pycnogeno, onion, maca, etc.) which would improve menopausal symptoms. 11. Subjects who regularly take medicine, functional foods and/or supplements (isoflavone, calcium, magnesium, CBP, MBP, vitamin D, etc.) which would affect the bone metabolism. 12. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 13. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 14. Subjects who participate in other clinical trials within the last one month prior to the this study. 15. Any other medical reasons judged by the principal investigator.
研究者
相似试验
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesEUCTR2017-002954-35-LTsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial)EUCTR2017-003510-16-LTexicon Pharmaceuticals, Inc.6,667
进行中（未招募）
1 期
A study in LupusPatients with Systemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2015-004404-35-ROEli Lilly and Company314
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of Study Drug INS1007 Administered Once Daily in Patients with Non-Cystic Fibrosis Bronchiectasis.on-Cystic Fibrosis BronchiectasisEUCTR2017-002533-32-ESInsmed Incorporated240
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety ofBIIB074 in Subjects With Neuropathic Pain FromLumbosacral RadiculopathyEUCTR2015-004775-78-ROConvergence Pharmaceuticals Ltd424